Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11913135 | 0.85 | ABL1 (0.33) | ALDH1A1GAAABL1 | |
| SCHEMBL1141792 | 0.80 | PDE8B (0.37) | ALDH1A1LMNAPOLBGAAABL1 | |
| SCHEMBL114987 | 0.76 | ALDH1A1 (0.33) | ALDH1A1LMNAPOLBGAAABL1 | |
| SCHEMBL1141595 | 0.74 | ERN1 (0.37) | ABL1CD274 | |
| SCHEMBL11911434 | 0.74 | ABL1 (0.39) | ALDH1A1GAAABL1 | |
| SCHEMBL11911433 | 0.72 | ABL1 (0.38) | ALDH1A1ABL1CD274 | |
| SCHEMBL14313780 | 0.71 | ALDH1A1 (0.40) | ALDH1A1LMNAPOLBGAAABL1 | |
| SCHEMBL11911432 | 0.70 | ABL1 (0.41) | ALDH1A1GAAABL1CD274 | |
| SCHEMBL13775461 | 0.70 | ABL1 (0.35) | ALDH1A1ABL1CD274 | |
| SCHEMBL457479 | 0.69 | CYP2C19 (0.33) | ALDH1A1LMNAPOLBGAAABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855222-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, RHOT2 | ALDH1A1 4395/4885LMNA 1711/4885POLB 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.